Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection

Michael J. Peluso^{1†*}, Zoe N. Swank^{2,3,4†}, Sarah A. Goldberg^{5†}, Scott Lu⁵, Thomas Dalhuisen⁵, Ella Borberg^{2,3,4}, Yasmeen Senussi^{2,3,4}, Michael A. Luna¹, Celina Chang Song¹, Alexus Clark¹, Andhy Zamora¹, Megan Lew¹, Badri Viswanathan⁵, Beatrice Huang¹, Khamal Anglin⁵, Rebecca Hoh¹, Priscila Y. Hsue⁶, Matthew S. Durstenfeld⁶, Matthew A. Spinelli¹, David V. Glidden⁵, Timothy J. Henrich⁷, J. Daniel Kelly⁵, Steven G. Deeks¹, David R. Walt^{2,3,4‡}, Jeffrey N. Martin^{5‡}

¹ Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San

Francisco, CA, USA

² Harvard Medical School, Boston, MA, USA

³ Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA

⁴ Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA

⁵ Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,

USA

⁶ Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA

⁷ Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA

^{†,‡}, equal contribution

* Corresponding Author: Michael J. Peluso Division of HIV, Infectious Diseases, and Global Medicine 1001 Potrero Ave San Francisco, CA 94110 415-476-4082 x 119 michael.peluso@ucsf.edu

Keywords: COVID-19, post-acute sequelae of SARS-CoV-2, Long COVID, viral persistence, antigen

1 ABSTRACT

24

2 BACKGROUND: Although RNA viruses like SARS-CoV-2 are generally thought to be transient, the 3 persistence of viral components beyond the acute phase can be driven by a variety of virologic and 4 immunologic factors. Recent studies have suggested that SARS-CoV-2 antigens may persist following 5 COVID-19 but were limited by a lack of comparison to a large number of true negative control samples. 6 7 METHODS: Using single molecule array (Simoa) assays for SARS-CoV-2 spike, S1, and nucleocapsid 8 antigen in plasma from 171 pandemic-era individuals in the post-acute phase of SARS-CoV-2 infection and 9 250 pre-pandemic control samples, we compared prevalence of antigen detection. We used logistic 10 regression models and prevalence ratios (PRs) to assess the relationship between demographic and 11 disease factors and antigen persistence. 12 13 RESULTS: Compared to the proportion of antigen positivity in the pre-pandemic controls (2%), detection of 14 any SARS-CoV-2 antigen was more frequent across all post-acute COVID-19 time bins (3-6 months: 15 12.6%, p<0.001; 6-10 months, 10.7%, p=0.0002; 10-14 months, 7.5%, p=0.017). These differences were 16 driven by spike protein for up to 14 months and nucleocapsid in the first 6 months after infection. The co-17 occurrence of multiple antigens at a single timepoint was uncommon. Hospitalization for acute COVID-19 18 (versus not hospitalized) and worse self-reported health during acute COVID-19 among those not 19 hospitalized (versus more benign illness) were associated with higher prevalence of post-acute antigen 20 detection (PR 1.86, p=0.03; PR 3.5, p=0.07, respectively) in the pandemic era. 21 22 CONCLUSIONS: Our findings provide strong evidence that SARS-CoV-2 antigens can persist beyond the 23 period of acute illness. The observation that more than 10% of plasma samples for over a year following

25 significant implications given the sheer number of people infected with SARS-CoV-2 to date. More work will

initial SARS-CoV-2 infection contain detectable viral antigen, which are potentially immunogenic, has

2 of 17

- 26 be needed to determine whether these antigens have a causal role in post-acute sequelae of SARS-CoV-2
- 27 infection (PASC).

28 BACKGROUND

29 Components of certain RNA viruses may persist for weeks or months following acute infection.¹ Although 30 such pathogens are generally thought to be transient, the persistence of viral components beyond the 31 acute phase can be driven by a variety of virologic and immunologic factors. In some cases, persistence of 32 active virus or viral antigens is associated with post-acute illness.²

33

Early in the pandemic, prolonged nasopharyngeal and/or gastrointestinal shedding of presumably non-34 infectious virus was observed in some individuals for 90 days or more, often despite clinical recovery.^{3,4} 35 36 More recently, evidence has suggested that SARS-CoV-2 protein and/or RNA can be detected beyond the acute phase of illness in a subset of individuals.⁵ For example, viral RNA or protein persistence has since 37 38 been identified in a variety of tissues in gut biopsy and autopsy studies for up to 2 years post-infection, although the clinical significance is unclear.⁶⁻⁹ Recent studies assessing protein and RNA in plasma 39 reported antigen detection in small cohorts of individuals post-COVID,^{10,11} but their conclusions were limited 40 41 by sporadic detection at or near the assay quantification limit and a lack of comparison to a large number of 42 true negative control samples.

43

44 In this study, we first used a pre-pandemic sample cohort to determine the true false positive prevalence of 45 the assay. We then measured the presence of SARS-CoV-2 antigen in plasma from a large, well-46 characterized cohort of persons in the post-acute phase of COVID-19 to determine whether antigen could be detected. We compared the prevalence after COVID-19 to that measured using plasma collected from 47 true negative control participants prior to the emergence of SARS-CoV-2 infection. We hypothesized that 48 49 the prevalence of antigen in plasma during the post-acute phase of COVID-19 would be significantly higher 50 than in control specimens and would correlate with parameters such as illness severity during the acute 51 phase of infection as well as clinical characteristics such as HIV infection status.

- 52
- 53

54 METHODS

55 Overall Design

In cross-sectional analyses, we compared participants in the post-acute phase of SARS-CoV-2 infection to persons studied prior to the COVID-19 pandemic for the presence of three different SARS-CoV-2 antigens in their plasma. Among the persons in the post-acute phase of SARS-CoV-2 infection, we also evaluated a variety of sociodemographic and clinical factors related to the acute phase of COVID-19 for their influence on SARS-CoV-2 antigen detection in the post-acute phase.

61

62 Participants

63 We studied two groups of participants. The first (hereafter known as pandemic-era) were participants in 64 the University of California, San-Francisco (UCSF)-based Long-term Impact of Infection with Novel 65 Coronavirus (LIINC) study (NCT04362150). Selection of participants into LIINC has been described 66 previously.¹² Briefly, using facility- and community-based advertising, we enrolled (beginning in April 2020) 67 consecutive adult volunteers who had earlier experienced their first episode of acute SARS-CoV-2 infection 68 (confirmed by detection of SARS-CoV-2 RNA or antigen) and who were at least two weeks removed from 69 their onset of COVID-19-related symptoms. Participants were examined at an initial study visit and every 70 four months thereafter. For the present analysis, we sampled participants who had the greatest number of 71 completed study visits (with stored plasma specimens) in the first 1.25 years following COVID-19 onset. 72 The second group of participants (hereafter known as pre-pandemic-era) were from the UCSF-based 73 Study of the Consequences of the Protease Era (SCOPE), an omnibus cohort study begun in 2001 74 originally focused on investigation of the pathogenesis of HIV infection. It contains participants at variety of 75 stages of HIV infection as well as ambulatory HIV-uninfected comparators, all of whom were volunteers 76 from the community. For the present analysis, we randomly selected, among participants with stored 77 plasma specimens prior to December 2019, four HIV-uninfected participants to every one HIV-infected participant, attempting to match the age and race/ethnicity distribution of the pandemic-era group. All 78 79 participants provided written informed consent.

80 Measurements

Questionnaire-based. In both groups, interviewer-administered questionnaires collected data on sociodemographic and economic characteristics. In the pandemic-era group, we also inquired about details concerning the acute phase of SARS-CoV-2 infection, including symptoms experienced in the first 3 weeks, self-reported worst perception of overall health on a 0 to 100 scale in the first 3 weeks, and whether hospitalization for COVID-19 occurred. The pandemic-era group also had all SARS-CoV-2 vaccinations recorded as well as any additional SARS-Co-V-2 infections since the initial infection.

87

88 Laboratory-based measurements. Peripheral blood was collected in EDTA-coated tubes and plasma 89 stored at -80° C using similar procedures in both the pre-pandemic era and pandemic-era groups. Using 90 once-thawed plasma, we employed single molecule array (Simoa) assays to measure SARS-CoV-2 antigens from spike, S1, and nucleocapsid proteins; detailed methods have been described elsewhere.^{10,13} 91 92 Briefly, plasma samples were centrifuged at 2000 x g for 10 minutes at 4 °C and treated with 5 mM dithiothreitol (Pierce[™] No-Weigh[™] Format, Thermo Fisher Scientific) and protease inhibitors (Halt[™] 93 94 Protease Inhibitor Cocktail, Thermo Fisher Scientific) for 15 minutes at 37° C. Each plasma sample was 95 diluted 8-fold in a 96-well plate with Sample Diluent Buffer (Quanterix) and analyzed automatically with a 96 three-step format on a HD-X Analyzer (Quanterix). In the first step, the plasma samples are incubated with 97 antibody-coated magnetic beads. Assays for S1, spike, and nucleocapsid were performed separately, 98 using antibodies against S1 (40150-D006, Sino Biological), S2 (MA5-35946, Invitrogen), and nucleocapsid 99 (40143-R004, Sino Biological) conjugated to carboxylated magnetic beads (Quanterix). In the second step, 100 the beads are resuspended in a solution of biotinylated detector antibodies. The same detector antibody 101 against S1 is used for the S1 and spike assays (LT-1900, Leinco) and another antibody against 102 nucleocapsid is used for the nucleocapsid assay (40143-R040, Sino Biological). In the third step, the beads 103 are incubated in a solution of streptavidin conjugated β -galactosidase and lastly resuspended in a solution 104 of resorufin β -D-galactopyranoside and loaded into a microwell array. The array is then sealed with oil and 105 imaged. Average enzyme per bead (AEB) values are calculated by the HD-X Analyzer software thereafter

and converted to concentration values based on a calibration curve fit with a four-parameter logistic
regression. Separately, the limit of detection (LOD) is calculated as the background AEB plus three times
the standard deviation and converted to a concentration. Only values above the LOD are reported and
values below the LOD are set to the LOD.

110

111 Statistical analysis

112 Up to 7 plasma timepoints (median 4, IQR 3-5) were assayed for SARS-CoV-2 antigens in the pandemic 113 era group and one timepoint in the pre-pandemic group. In each plasma specimen tested, antigen 114 detection was defined in four ways: a) presence or absence on each of three individual antigen assays; 115 and b) presence of at least one of the three antigens (vs absence on all three). When comparing antigen 116 prevalence in the pandemic-era group to the pre-pandemic era group, we defined three periods of time for 117 the pandemic-era group: 3.0-6.0 months, 6.1-10.0 months, and 10.1-14 months post-onset of COVID-19 118 symptoms. If there was more than one time point per person in a given time period, we chose the 119 timepoint closest to the midpoint of the period. Comparison between groups were expressed with 120 prevalence ratios and differences. All analyses were performed using Stata version 17.0 (StataCorp, 121 College Station, Texas).

122

123 **RESULTS**

124 Study participants

125 We studied 171 pandemic-era participants over 660 timepoints between 0.9 and 15.4 months following

initial SARS-CoV-2 symptom onset (Table 1). The pandemic-era group was 50% female, and median age

127 was 46 years (IQR 37-57). The parent study was deliberatively enriched for people with HIV (PWH); as a

result, this comorbidity was relatively common in the study population (n=25, 15%). The pre-pandemic-era

group (n=250) was similar in comparison, although included a lower proportion of women (22%).

130

131 Antigen detection

7 of 17

At least one SARS-CoV-2 antigen was detected in 5/250 (2%) pre-pandemic samples. In the pre-pandemic samples, spike was detected in 3/250 (1.2%) cases, S1 in 3/250 (1.2%) cases, and N in 2/250 (0.8%) cases. These values represent prevalence of false positivity. Of those with false positive detectable antigen, positive Spike values were: 83.46 pg/mL, 609.96 pg/mL, and 646.02 pg/mL; positive S1 values were: 34.67 pg/mL, 115.89 pg/mL, and 285.31 pg/mL; positive N values were: 649.28 pg/mL and 5716.32 pg/mL.

138

Compared to the proportion of antigen positivity in the pre-pandemic group, detection of any SARS-CoV-2 antigen was more frequent across all pandemic-era time bins (Figure 1a; Supplemental Table 1). These differences were driven by spike protein for up to 14 months and nucleocapsid in the first 6 months after infection (Figure 1b-d).

143

144 Of the 660 pandemic-era timepoints studied, 61 (9.2%) timepoints representing 25% of participants had 145 one or more detectable SARS-CoV-2 antigens (Figure 2). The most commonly detected antigen was Spike 146 (n=33, 5.0%), followed by S1 (n=15, 2.3%) and N (n=15, 2.3%). In most cases (59/61, 96.7%) only a single 147 antigen was detected. The co-occurrence of multiple antigens at a single timepoint was uncommon. In 148 2/61 cases (4.9%), two antigens were simultaneously detected (one case was positive for S1 and N; a 149 second case was positive for Spike and N). In no case were all three antigens detected simultaneously. Of 150 those with detectable antigen, the median Spike concentration was 27.7 pg/mL (IQR 20.5-33.7), median S1 151 concentration was 31.2 pg/mL (IQR 20.5-193.0), and median N was 23.6 pgmL (IQR 6.46-62.0).

152

It was also uncommon for individuals to demonstrate the presence of antigen at multiple timepoints. Of 159 participants who had multiple timepoints studied, 29 (18.2%) had antigen detected at a single post-acute timepoint, 10 (6.3%) had antigen detected at two post-acute timepoints, and one (0.63%) had antigen detected at two post-acute timepoints, and one (0.63%) had antigen detected at three, four, and five post-acute timepoints, respectively (Figure 3). Most timepoints at which antigen was detected (51/61, 84%) occurred before the participant had ever received a SARS-CoV-2

- vaccine (Figure 3). There were five instances in which antigen was detected within three weeks of a SARSCoV-2 vaccine dose (three for S1, one for Spike, and one for N).
- 160
- 161 Determinants of antigen positivity among pandemic-era participants

Finally, we examined determinants of antigen detection among the pandemic-era participants. We found no strong evidence of an association between age, sex, race/ethnicity, HIV status, or body mass index (BMI) with antigen positivity. In contrast, we found strong evidence for an influence of severity of the acute phase of infection. As compared to those not hospitalized, participants who required hospitalization for acute COVID-19 were nearly twice as likely to have antigen detected (prevalence ratio [PR] 1.86, p=0.03). Among those not hospitalized for COVID-19, those with the worst self-report of acute illness were over 3 times as likely to have antigen detected as compared to those with the most benign self-reports (PR 3.5,

- 169 p=0.07), an absolute difference of nearly 30%.
- 170

171 **DISCUSSION**

172 In comparison to pre-pandemic samples, we identified increased prevalence of SARS-CoV-2 antigen 173 detection for up to 14 months following confirmed SARS-CoV-2 infection. This observation builds upon 174 earlier work in smaller cohorts^{10,11} and provides strong evidence that SARS-CoV-2 should be added to the list of RNA viruses whose components may persist beyond the period of acute illness.¹⁰ Although a 175 176 definitive link between antigen persistence and post-acute sequelae (e.g., Long COVID symptoms, 177 cardiovascular disease, stroke, blood clots, etc.) has yet to be confirmed, the observation that more than 178 10% of plasma samples for over a year following initial SARS-CoV-2 infection contain detectable viral antigens, which are potentially immunogenic,¹⁴⁻¹⁶ has significant implications given the sheer number of 179 180 people infected with SARS-CoV-2 to date.

181

Our study addresses two key criticisms of prior work evaluating SARS-CoV-2 antigen persistence.⁵ First,
 our direct comparison with SARS-CoV-2 antigen signal measured in pre-pandemic control samples

mitigates the concern that antigen detection in the post-acute phase can be entirely explained by falsepositive signal. Second, by including many specimens banked prior to the receipt of any SARS-CoV-2 vaccine, we were able to determine that most antigen detection occurred in these pre-vaccine samples, suggesting that this finding is driven by SARS-CoV-2 infection and not prior vaccination (although one would not expect N protein to be present in relation to a SARS-CoV-2 vaccine).

189

The proportion of antigen positivity was lower in our study than in a prior report using this assay.¹⁰ The lower prevalence detected in our study may be because we enrolled individuals in the post-acute phase regardless of illness severity or the presence of post-acute symptoms. In contrast, prior reports studied those seeking clinical care in Long COVID clinics, many of whom were highly symptomatic. Further work is needed to assess whether antigen persistence is a driver of the post-acute sequelae of SARS-CoV-2 infection, or whether it is simply a remnant of prior infection with little or no consequences.

196

197 As in prior reports, we found antigen detection to be sporadic in individuals in whom it was present. It is 198 possible that small variations over time could result in periods during which antigen is less detectable using 199 current assays. Alternatively, antigen release from tissue reservoirs may in fact be intermittent, driven by 200 host factors that have not yet been determined but might include differential release from tissues based on 201 other factors such as the timing of a meal, hormonal factors, etc. The finding of an association between the 202 severity of the acute phase illness and antigen detection in the post-acute phase also suggests that the 203 burden of infectious antigen established early in the disease course may determine the likelihood of 204 antigen persistence. This might offer one explanation for the protective effect of SARS-CoV-2 vaccination or antiviral therapy.¹⁷⁻²⁰ This finding also merits further investigation. 205

206

207 This study adds substantially to prior work that has challenged the framework that SARS-CoV-2 infection is

transient in all cases.⁵ The finding that the virus can evolve over months in immunocompromised

209 individuals provides proof that persistent infection is possible.⁸ Among immunocompetent individuals,

10 of 17

210 evolving B cell immunity provided early albeit indirect evidence that SARS-CoV-2 infection can be sustained.⁶ More recently, an autopsy study showed widespread sub-genomic RNA in tissues of decedents 211 212 up to 6 months post-COVID,⁷ and we have reported SARS-CoV-2 spike RNA detection in gut biopsies for up to 2.5 years post-COVID.⁹ SARS-CoV-2 antigens, particularly spike protein and its components, are 213 known to be highly immunogenic.¹⁴⁻¹⁶ These antigens have been shown to induce inflammatory cytokine 214 215 responses as well as dysregulation of fibrinogen, complement proteins, and endothelial cells. Thus, the 216 consistent identification of post-acute antigen in a subset of individuals following SARS-CoV-2 infection 217 provides additional rationale for interventions meant to reduce or eliminate these antigens, either with 218 antiviral drugs (if viral replication is present) or other drugs that could neutralize protein, clear infected cells, 219 and/or modulate the immune response to these antigens (e.g., monoclonal antibodies). Such studies are 220 now underway (NCT05877507, NCT05595369, NCT05576662, NCT05668091).

221

222 The strength of our analysis is the comparison to definitively negative pre-pandemic control specimens, 223 demonstrating long-term antigen persistence in a small but significant proportion of individuals following 224 COVID-19. However, the study has several limitations. The cohort was a convenience sample and not 225 representative of all individuals experiencing SARS-CoV-2 infection during the period of interest. We 226 studied samples preceding the emergence of the Omicron strains, and further work will be needed to 227 assess the prevalence of antigen detection following infection with circulating SARS-CoV-2 variants. While 228 our participants did not have known or clinically suspected reinfections prior to antigen detection, they were 229 not systematically assessed for asymptomatic SARS-CoV-2 infection at each time point. Finally, even 230 though the Simoa is highly sensitive, it is possible that more sensitive assays will be needed, particularly as 231 the source of persistent SARS-CoV-2 antigen might not result in the production of a readily detectable 232 systemic infection and many detected values were near the assay limit. Our team is developing such an assay (MOSAIC).²¹ 233

In summary, we described post-acute antigen detection in a cohort of 171 individuals in the post-acute
 phase following SARS-CoV-2 infection. In comparison to pre-pandemic samples, we demonstrated an

11 of 17

- 236 increased prevalence of SARS-CoV-2 antigen detection for over 1 year following initial infection. While the
- 237 overall prevalence of antigen detection was lower than in prior work comprising a different study
- 238 population, this finding has major implications given the scale of the pandemic and the knowledge that
- 239 SARS-CoV-2 spike protein is highly immunogenic. Taken together, these results provide strong evidence
- that SARS-CoV-2 antigen persists in the post-acute phase in some individuals. However, determination of
- 241 whether antigen persistence is causally related to symptoms will require larger studies of carefully
- 242 characterized samples, better delineating the test characteristics of these assays, and the use of
- 243 experimental medicine to probe the biology of this mechanistic pathway.

244 FOOTNOTES

245 Acknowledgements

246 We are grateful to the study participants and their medical providers. We acknowledge current LIINC 247 clinical study team members Grace Anderson, Kofi Asare, Melissa Buitrago, Alexus Clark, Emily Conway, 248 Marin Ewing, Emily Fehrman, Tony Figueroa, Diana Flores, Marian Kerbleski, Megan Lew, Antonio 249 Rodriguez, Justin Romero, Dylan Ryder, Matthew So, Viva Tai, Alex Tang, Meghann Williams, and Andhy 250 Zamora; and current LIINC laboratory team members Amanda Buck, Brian LaFranchi, and David Maison. 251 We thank Jessica Chen, Aidan Donovan, Carrie Forman, and Rania Ibrahim for assistance with data entry 252 and review. We thank the UCSF AIDS Specimen Bank for processing specimens and maintaining the 253 LIINC biospecimen repository. We are grateful to Elnaz Eilkhani and Monika Deswal for regulatory support.

- 254 We also acknowledge all former LIINC team members.
- 255
- 256 Author Contributions
- 257 Designed the study: MJP, SGD, DRW, JNM
- 258 Designed the cohort: MJP, PYH, MSD, TJH, JDK, SGD, JNM
- 259 Collected biospecimens and clinical data: MJP, RH, ML, CCS, AC, AZ, ML, BH, KA.
- 260 Performed the assays: ZS, EB, YS in the laboratory of DRW.
- 261 Managed the data: SL, TD, BV.
- 262 Analyzed the data: MJP, SAG, DVG.
- 263 Wrote the manuscript: MJP, SGD, JDK, DRW, JNM.
- 264 Edited the manuscript: All authors.
- 265 Approved the manuscript: All authors.
- 266
- 267 Funding

- This work was supported by funding from the PolyBio Research Foundation to support the LIINC Clinical Core, as well as support from NIH/NIAID 3R01AI141003-03S1, NIH/NIAID R01AI158013, and NIH/NIAID K23AI134327.
- 271
- 272 Conflicts of Interest
- 273 MJP reports consulting for Gilead Sciences and AstraZeneca, outside the submitted work. DRW has a
- financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay
- 275 platform. He is an inventor of the Simoa technology, a founder of the company, and also serves on its
- 276 Board of Directors. Dr. Walt's interests were reviewed and are managed by Mass General Brigham and
- 277 Harvard University in accordance with their conflict-of-interest policies.

278 **REFERENCES**

- Griffin DE. Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol
 2022;20(6):e3001687. DOI: 10.1371/journal.pbio.3001687.
- Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nature
 Medicine 2022;28(5):911-923. DOI: 10.1038/s41591-022-01810-6.
- Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nature Reviews
 Microbiology 2023;21(3):147-161. DOI: 10.1038/s41579-022-00822-w.
- 285 4. Owusu D, Pomeroy MA, Lewis NM, et al. Persistent SARS-CoV-2 RNA Shedding Without Evidence
- 286 of Infectiousness: A Cohort Study of Individuals With COVID-19. The Journal of Infectious Diseases
- 287 2021;224(8):1362-1371. DOI: 10.1093/infdis/jiab107.
- Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of
 COVID-19 (PASC). Nat Immunol 2023. DOI: 10.1038/s41590-023-01601-2.
- Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature
 2021;591(7851):639-644. DOI: 10.1038/s41586-021-03207-w.
- Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body
 and brain at autopsy. Nature 2022;612(7941):758-763. DOI: 10.1038/s41586-022-05542-y.
- 294 8. Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen
- 295 Persistence in Inflammatory Bowel Diseases. Gastroenterology 2022;163(2):495-506 e8. DOI:

296 10.1053/j.gastro.2022.04.037.

- Peluso MJ, Ryder D, Flavell R, et al. Multimodal Molecular Imaging Reveals Tissue-Based T Cell
 Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19. medRxiv
- 299 2023:2023.07.27.23293177. DOI: 10.1101/2023.07.27.23293177.
- 300 10. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent Circulating Severe

301 Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus

302 Disease 2019 Sequelae. Clin Infect Dis 2023;76(3):e487-e490. DOI: 10.1093/cid/ciac722.

- 303 11. Craddock V, Mahajan A, Spikes L, et al. Persistent circulation of soluble and extracellular vesicle-
- 304 linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol

305 2023;95(2):e28568. DOI: 10.1002/jmv.28568.

- 306 12. Peluso MJ, Kelly JD, Lu S, et al. Persistence, Magnitude, and Patterns of Postacute Symptoms and
- 307 Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for

308 Measurement. Open Forum Infect Dis 2022;9(2):ofab640. DOI: 10.1093/ofid/ofab640.

Wu D, Milutinovic MD, Walt DR. Single molecule array (Simoa) assay with optimal antibody pairs for
 cvtokine detection in human serum samples. Analyst 2015;140(18):6277-82. DOI:

311 10.1039/c5an01238d.

14. Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. SARS-CoV-2 spike protein

induces inflammation via TLR2-dependent activation of the NF-κB pathway. Elife 2021;10 (In eng).

314 DOI: 10.7554/eLife.68563.

315 15. Ryu JK, Sozmen EG, Dixit K, et al. SARS-CoV-2 spike protein induces abnormal inflammatory
316 blood clots neutralized by fibrin immunotherapy. bioRxiv 2021. DOI: 10.1101/2021.10.12.464152.

16. Liang S, Bao C, Yang Z, et al. SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary

318 inflammation via reduced mitophagy. Signal Transduction and Targeted Therapy 2023;8(1):108.

319 DOI: 10.1038/s41392-023-01368-w.

Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine
 2022;28(7):1461-1467. DOI: 10.1038/s41591-022-01840-0.

18. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M. Association Between

- BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health
 Care Workers. JAMA 2022. DOI: 10.1001/jama.2022.11691.
- Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ
 2023;381:e074572. DOI: 10.1136/bmj-2022-074572.
- Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19
 Condition. JAMA Intern Med 2023. DOI: 10.1001/jamainternmed.2023.0743.

- 329 21. Wu C, Dougan TJ, Walt DR. High-Throughput, High-Multiplex Digital Protein Detection with
- Attomolar Sensitivity. ACS Nano 2022;16(1):1025-1035. DOI: 10.1021/acsnano.1c08675.

331

Table 1. Characteristics of study participants.

Characteristic	Pandemic Era	Pre-pandemic Era
Characteristic	(n = 171)	(n = 250)
Age, years	46	48
	(37-57) ^a	(36-58) ^a
	(19-85) ^b	(22-83) ^b
Female Birth Sex	86 (50%)	56 (22%)
Sexual Orientation ^c		
Asexual	1 (0.6%)	0 (0.0%)
Bisexual	1 (0.6%)	24 (9.6%)
Gay/lesbian	34 (20%)	98 (39%)
Straight/heterosexual	110 (64%)	113 (45%)
Other	1 (0.6%)	0 (0%)
Race/Ethnicity ^c	, , , , , , , , , , , , , , , , , , ,	· · · ·
Hispanic/Latino	47 (28%)	41 (16%)
White	92 (54%)	104 (42%)
Black/African American	8 (4.7%)	76 (30%)
Asian	17 (9.9%)	29 (12%)
Pacific Islander/Native Hawaiian	3 (1.8%)	0 (0.0%)
Education ^c	, , , , , , , , , , , , , , , , , , ,	
Any high school or less	33 (19%)	79 (32%)
Any college	69 (40%)	117 (47%)
Any graduate school	69 (40%)	52 (21%) [′]
Income ^c	X ,	
\$30.000 or less	24 (14%)	115 (46%)
\$30,001 to \$70,000	24 (14%)	36 (14%)
More than \$70,000	99 (58%)	40 (16%)
Body Mass Index ^c	(),	()
Less than 18.5 kg/m ²	2 (1.2%)	5 (2.0%)
18.5 kg/m ² to 24.9 kg/m ²	58 (34%)	116 (46%)
25.0 kg/m^2 to 29.9 kg/m ²	49 (29%)	68 (27%)
More than 30.0 kg/m ²	61 (36%)	50 (20%)
HIV Seropositive	25 (15%)	50 (20%)
Hospitalized During Acute COVID Infection ^c	33 (19%)	N/A
Symptom Count During Acute COVID Infection	9 ` ´	N/A
, i 5	(6-12) ^a	
	(0-25) ^b	
Health Score at Worst Point in COVID Illness ^c	45	N/A
	(25-60) ^a	
	(0-100) ^b	
Statement of Health ^c	,	
Excellent	N/A	62 (25%)
Very Good	N/A	82 (33%)
Good	N/A	65 (26%)
Fair	N/A	26 (10%)
Poor	N/A	3 (1.2%)
Any high school or less Any college Any graduate school Income ^c \$30,000 or less \$30,001 to \$70,000 More than \$70,000 Body Mass Index ^c Less than 18.5 kg/m ² 18.5 kg/m ² to 24.9 kg/m ² 25.0 kg/m ² to 29.9 kg/m ² More than 30.0 kg/m ² HIV Seropositive ^c Hospitalized During Acute COVID Infection ^c Symptom Count During Acute COVID Infection Health Score at Worst Point in COVID Illness ^c Statement of Health ^c Excellent Very Good Good Fair Poor	33 (19%) 69 (40%) 69 (40%) 24 (14%) 99 (58%) 2 (1.2%) 58 (34%) 49 (29%) 61 (36%) 25 (15%) 33 (19%) 9 (6-12) ^a (0-25) ^b 45 (25-60) ^a (0-100) ^b N/A N/A N/A N/A N/A	79 (32%) 117 (47%) 52 (21%) 115 (46%) 36 (14%) 40 (16%) 5 (2.0%) 116 (46%) 68 (27%) 50 (20%) 50 (20%) N/A N/A N/A N/A 62 (25%) 82 (33%) 65 (26%) 26 (10%) 3 (1.2%)

^aMedian (interquartile range)

^bAbsolute range

^cMissing and nonresponse. Sexual orientation: 35 missing, 3 questioning/unsure, 1 prefer not to answer; race/ethnicity: 4 missing; education: 2 missing; income: 3 missing, 80 prefer not to answer; BMI: 12 missing; hospitalization: 1 missing; health score: 82 missing; statement of health: 12 missing

Table 2. Association between sociodemographic and clinical characteristics and antigen positivity.

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p- value
Age, years				
Less than 40	0.26	Ref	Ref	
40-65	0.21	0.81 (0.45 to 1.44)	-0.05 (-0.19 to 0.09)	0.47
65 or more	0.40	1.52 (0.71 to 3.25)	0.14 (-0.14 to 0.41)	0.31
Sex				
Female	0.20	Ref	Ref	
Male	0.29	1.49 (0.87 to 2.55)	0.10 (-0.03 to 0.23)	0.15
Race/ethnicity				
White	0.23	Ref	Ref	
Hispanic/Latino	0.32	1.40 (0.80 to 2.46)	0.09 (-0.07 to 0.25)	0.25
Black/African American	0.25	1.10 (0.31 to 3.87)	0.02 (-0.29 to 0.33)	0.89
Asian	0.18	0.77 (0.26 to 2.32)	-0.05 (-0.25 to 0.15)	0.64
Pacific Islander/Native Hawaiian	0.33	1.46 (0.28 to 7.59)	0.11 (-0.44 to 0.65)	0.68
HIV				
No	0.25	Ref	Ref	
Yes	0.24	0.97 (0.46 to 2.07)	-0.01 (-0.19 to 0.18)	0.94
Body Mass Index ^a		, , ,		
Less than 18.5 kg/m ²	-	-	-	-
18.5 kg/m^2 to 24.9 kg/m^2	0.21	Ref	Ref	
25.0 kg/m^2 to 29.9 kg/m ²	0.29	1.38 (0.70 to 2.71)	0.08 (-0.09 to 0.24)	0.35
More than 30.0 kg/m ²	0.26	1.27 (0.66 to 2.45)	0.06 (-0.10 to 0.21)	0.48
Hospitalized During Acute COVID	O Infection			
No	0.21	Ref	Ref	
Yes	0.39	1.86 (1.09 to 3.17)	0.18 (0.00 to 0.36)	0.03
Symptom Count During Acute Co	OVID Infection	1 ^{b,c}	, , , , , , , , , , , , , , , , , , ,	
0-5 symptoms	0.23	Ref	Ref	
6-8 symptoms	0.19	0.86 (0.34 to 2.19)	-0.03 (-0.23 to 0.17)	0.75
9-11 symptoms	0.10	0.46 (0.13 to 1.61)	-0.12 (-0.31 to 0.06)	0.22
12+ symptoms	0.29	1.27 (0.56 to 2.85)	0.06 (-0.14 to 0.26)	0.57
Health Score at Worst Point in C	OVID Infectio	n ^{b,d}	· · · · · · · · · · · · · · · · · · ·	
>60	0.12	Ref	Ref	
50-60	0.13	1.11 (0.21 to 5.99)	0.01 (-0.19 to 0.22)	0.90
30-49	0.20	1.70 (0.35 to 8.25)	0.08 (-0.15 to 0.32)	0.51
<30	0.41	3.50 (0.84 to 14.6)	0.29 (0.01 to 0.58)	0.07

^aIndividuals whose BMI was <18.5 kg/m² (N=2) were omitted from the analyses due to collinearity

^bAnalyses only conducted amongst participants who were not hospitalized during their acute COVID infection

^cN= 138 ^dN= 77

Figure 1. (a) Prevalence of SARS-CoV-2 antigen in plasma in the post-acute phase of COVID-19 in comparison to prevalence of false positivity in pre-pandemic control plasma. (b) Spike antigen prevalence. (c) Nucleocapsid antigen presence. (d) S1 presence. P-values represent Chi-square and Fisher's 2-sided exact test as appropriate.



Figure 2. Plasma antigen measurements. Dashed lines indicate limit of quantification for each analyte. Y-axis refers to log-transformed concentration, units are pg/mL.



Figure 3. Antigen measurements over time in pandemic-era participants with at least one positive antigen. Blue indicates spike, green nucleocapsid, and red S1. Horizontal dotted lines represent the assay limit of detection for each antigen. Vertical dotted lines indicate timing of any SARS-CoV-2 vaccine relative to antigen.





Supplemental Table 1.

Any SARS-CoV-2 Antigen

Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95% CI; p value
Pre-pandemic	250	5 (2.00%)	Reference
3 to 6.0 months after infection	151	19 (12.58%)	0.1058 (0.0502 to 0.1615; p-value < 0.001)
6 to 10.0 months	131	14 (10.69%)	0.0869 (0.0312 to 0.1425; p-value = 0.0002)
10 to 14 months*	122	9 (7.38%)	0.0538 (0.0042 to 0.0103; p-value = 0.017)

*Fisher's 2-sided exact-test

Spike*

Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95%
Pre-pandemic	250	3 (1.20%)	Reference
3 to 6.0 months after infection	151	9 (5.96%)	0.0476 (0.0075 to 0.0877; p-value = 0.012)
6 to 10.0 months	131	7 (5.34%)	0.0414 (0.0006 to 0.0822; p-value = 0.036)
10 to 14 months	122	5 (4.10%)	0.0289 (-0.0087 to 0.0667; p-value = 0.12)

*Fisher's 2-sided exact-test

N*

IN			
Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95% Cl; p value
Pre-pandemic	250	2 (0.80%)	Reference
3 to 6.0 months after infection	151	7 (4.64%)	0.0384 (0.0031 to 0.0737; p-value = 0.030)
6 to 10.0 months	131	3 (2.29%)	0.0149 (-0.0130 to 0.0428; p-value = 0.34)
10 to 14 months	122	2 (1.64%)	0.0084 (-0.0167 to 0.0335; p-value = 0.60)

*Fisher's 2-sided exact-test

Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95% Cl; p value
Pre-pandemic	250	3 (1.20%)	Reference
3 to 6.0 months after infection	151	4 (2.65%)	0.0145 (-0.0145 to 0.0434; p-value = 0.43)
6 to 10.0 months	131	4 (3.05%)	0.0185 (-0.0139 to 0.0509; p-value = 0.24)
10 to 14 months	122	3 (2.46%)	0.0126 (-0.0180 to 0.0432; p-value = 0.40)

*Fisher's 2-sided exact-test

Supplemental Table 2a. Association between sociodemographic characteristics and ever S1 antigen positivity

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p- value	
Age, years					
Less than 40	0.05	Ref	Ref		
40-65	0.04	0.77 (0.18 to 3.32)	-0.01 (-0.08 to 0.06)	0.72	
65 or more	0.27	5.07 (1.26 to 20.3)	0.21 (-0.02 to 0.45)	0.02	
Sex					
Female	0.05	Ref	Ref		
Male	0.08	1.77 (0.54 to 5.85)	0.04 (-0.04 to 0.11)	0.35	
Race/ethnicity ^a					
White	0.08	Ref	Ref		
Hispanic/Latino	0.06	0.84 (0.23 to 3.11)	-0.01 (-0.10 to 0.08)	0.79	
Black/African American	-	-	-	-	
Asian	0.06	0.77 (0.10 to 5.93)	-0.02 (-0.14 to 0.11)	0.80	
Pacific Islander/Native Hawaiian	-	-	-	-	
HIV		_ /			
No	0.07	Ref	Ref		
Yes	0.04	0.58 (0.08 to 4.39)	-0.03 (-0.12 to 0.06)	0.60	
Body Mass Index ^a					
Less than 18.5 kg/m ²	-	-	-	-	
18.5 kg/m ² to 24.9 kg/m ²	0.12	Ref	Ref		
25.0 kg/m ² to 29.9 kg/m ²	0.04	0.34 (0.07 to 1.56)	-0.08 (-0.18 to 0.02)	0.16	
More than 30.0 kg/m ²	0.03	0.27 (0.06 to 1.26)	-0.09 (-0.18 to 0.01)	0.09	
Hospitalized During Acute COVII			Def		
NO Xa a	0.06			0.50	
Yes Summtom Count During Acute C	0.09	1.56 (0.43 to 5.57)	0.03 (-0.07 to 0.14)	0.50	
Symptom Count During Acute C					
0-5 symptoms	0.10	Ref	Ref	0.50	
6-8 symptoms	0.06	0.57 (0.10 to 3.24)	-0.04 (-0.17 to 0.09)	0.53	
9-11 symptoms	0.03	0.36 (0.04 to 3.26)	-0.06 (-0.19 to 0.06)	0.36	
12+ symptoms	0.05	0.49 (0.09 to 2.79)	-0.05 (-0.17 to 0.07)	0.42	
Health Score at Worst Point in C		Def	Def		
>60	0.06			0.74	
5U-6U	0.09	1.48 (0.14 to 15.3)	0.03 (-0.13 to 0.19)	0.74	
30-49	0.15	2.55 (0.29 to 22.7)	0.09 (-0.10 to 0.29)	0.39	
<ju< td=""><td>-</td><td>-</td><td>-</td><td>-</td></ju<>	-	-	-	-	

^aIndividuals who are Black/African American (N=8) or Pacific Islander/Native Hawaiian (N=3), whose BMI was <18.5 kg/m² (N=2), or whose health score was <30 (N=17) were omitted from the analyses due to collinearity

(N=2), or whose health score was <30 (N=17) were omitted from the analyses due to collinearity ^bAnalyses only conducted amongst participants who were not hospitalized during their acute COVID infection

^cN= 138 ^dN= 60

Supplemental Table 2b. Association between sociodemographic characteristics and ever spike antigen positivity

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p- value
Age, years				
Less than 40	0.18	Ref	Ref	
40-65	0.13	0.75 (0.35 to 1.60)	-0.04 (-0.16 to 0.08)	0.46
65 or more	0.20	1.14 (0.36 to 3.64)	0.02 (-0.20 to 0.25)	0.83
Sex				
Female	0.13	Ref	Ref	
Male	0.18	1.38 (0.67 to 2.83)	0.05 (-0.06 to 0.16)	0.38
Race/ethnicity ^a				
White	0.15	Ref	Ref	
Hispanic/Latino	0.19	1.26 (0.59 to 2.70)	0.04 (-0.10 to 0.17)	0.56
Black/African American	0.25	1.64 (0.45 to 6.01)	0.10 (-0.21 to 0.41)	0.48
Asian	0.06	0.39 (0.05 to 2.77)	-0.09 (-0.23 to 0.04)	0.33
Pacific Islander/Native Hawaiian	-	-	-	-
HIV				
No	0.15	Ref	Ref	
Yes	0.16	1.06 (0.40 to 2.83)	0.01 (-0.15 to 0.16)	0.90
Body Mass Index ^a				
Less than 18.5 kg/m ²	-	-		-
18.5 kg/m ² to 24.9 kg/m ²	0.09	Ref	Ref	
25.0 kg/m ² to 29.9 kg/m ²	0.20	2.37 (0.86 to 6.48)	0.12 (-0.02 to 0.25)	0.09
More than 30.0 kg/m ²	0.18	2.09 (0.77 to 5.67)	0.09 (-0.03 to 0.22)	0.14
Hospitalized During Acute COVII	D Infection	_ /	_ /	
No	0.15	Ref	Ref	
Yes	0.15	0.99 (0.40 to 2.43)	-0.00 (-0.14 to 0.14)	0.98
Symptom Count During Acute C	OVID Infection	1 ^{D,C}		
0-5 symptoms	0.16	Ref	Ref	
6-8 symptoms	0.14	0.86 (0.27 to 2.71)	-0.02 (-0.19 to 0.15)	0.80
9-11 symptoms	0.07	0.43 (0.09 to 2.05)	-0.09 (-0.25 to 0.07)	0.28
12+ symptoms	0.21	1.33 (0.49 to 3.59)	0.05 (-0.13 to 0.23)	0.57
Health Score at Worst Point in C	OVID Illness ^{b,c}	1		
>60	0.12	Ref	Ref	
50-60	0.09	0.74 (0.11 to 4.79)	-0.03 (-0.22 to 0.16)	0.75
30-49	0.05	0.43 (0.04 to 4.35)	-0.07 (-0.25 to 0.11)	0.47
<30	0.35	3.00 (0.70 to 12.9)	0.24 (-0.04 to 0.51)	0.12

^aIndividuals who are Pacific Islander/Native Hawaiian (N=3) or whose BMI was <18.5 kg/m² (N=2) were omitted from the analyses due to collinearity

^bAnalyses only conducted amongst participants who were not hospitalized during their acute COVID infection ^cN= 138

 $^{d}N = 77$

Supplemental Table 2c. Association between sociodemographic characteristics and ever N antigen positivity

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p- value	
Age, years					
Less than 40	0.05	Ref	Ref		
40-65	0.07	1.34 (0.36 to 5.01)	0.02 (-0.06 to 0.10)	0.66	
65 or more	-	-	-	-	
Sex					
Female	0.05	Ref	Ref		
Male	0.07	1.52 (0.44 to 5.21)	0.02 (-0.05 to 0.09)	0.51	
Race/ethnicity					
White	0.02	Ref	Ref		
Hispanic/Latino	0.11	4.89 (0.98 to 24.4)	0.08 (-0.01 to 0.18)	0.05	
Black/African American	0.13	5.75 (0.58 to 57.1)	0.10 (-0.13 to 0.34)	0.15	
Asian	0.06	2.71 (0.26 to 28.4)	0.04 (-0.08 to 0.15)	0.41	
Pacific Islander/Native Hawaiian	0.33	15.3 (1.85 to 127)	0.31 (-0.22 to 0.85)	0.03	
HIV					
No	0.05	Ref	Ref		
Yes	0.08	1.46 (0.33 to 6.51)	0.03 (-0.09 to 0.14)	0.62	
Body Mass Index ^a					
Less than 18.5 kg/m ²	-	-	-	-	
18.5 kg/m^2 to 24.9 kg/m ²	0.05	Ref	Ref		
25.0 kg/m^2 to 29.9 kg/m ²	0.04	0.79 (0.14 to 4.56)	-0.01 (-0.09 to 0.07)	0.79	
More than 30.0 kg/m ²	0.08	1.58 (0.39 to 6.36)	0.03 (-0.06 to 0.12)	0.51	
Hospitalized During Acute COVI	D Infection				
No	0.02	Ref	Ref		
Yes	0.21	9.69 (2.64 to 35.6)	0.19 (0.05 to 0.33)	<0.001	
Symptom Count During Acute C	OVID Infection	n ^b			
0-5 symptoms	-	-	-	-	
6-8 symptoms	-	-	-	-	
9-11 symptoms	-	-	-	-	
12+ symptoms	-	-	-	-	
Health Score at Worst Point in COVID Illness ^b					
>60	-	-	-	-	
50-60	-	-	-	-	
30-49	-	-	-	-	
<30	-	-	-	-	

^aIndividuals who were 65 years or older (N=15) or whose BMI was <18.5 kg/m² (N=2) were omitted from the analyses due to collinearity ^bAnalyses were omitted due to complete collinearity